Cancer Market Growth

Cancer Market Growth Dependent Upon Success of Targeted Therapies - Will They Provide Enough Benefit to Patients to Succeed?
Frost & Sullivan Thursday, September 1, 2005
Source: Quarterly Analyst Briefing on Cancer Market Growth

The cancer therapy market is undergoing a shift in the revenue generation. The older chemotherapeutic drugs are no longer the sole source of revenue generation and the future of this market is dependent upon the success of targeted therapies.

These therapies, such as Rituxan/MabThera and Glivec are already dominating their markets in terms of revenues and this trend of targeted therapies is now moving into the larger cancers that have tremendouspatient-population.

The question is: can targeted therapies be as successful as they need to be to drive revenue and at the same time provide substantial benefit to patients?

"The targeted therapy segment in the global cancer market is expected to drive revenue growth through 2011. Targeted therapies are used in conjunction with chemotherapy and therefore provide market expansion instead of competition with existing agents," says Frost & Sullivan's Research Analyst

for the Pharmaceuticals group, Jason McKinnie. "Pharmaceutical and biotechnology companies are focusing more attention on specific cancer targets and are embracing targeted therapy as the future of cancer treatment."